

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Redpoint Bio Corporation	05/23/2013
RECEIVING PARTY DATA	
Name:	JANSSEN PHARMACEUTICALS, INC.
Street Address:	1125 Trenton-Harbourton Rd.
City:	Titusville
State/Country:	NEW JERSEY
Postal Code:	08560
PROPERTY NUMBERS Total: 4	
Property Type	Number
Patent Number:	7875452
Patent Number:	7749730
Patent Number:	7674831
Patent Number:	8193168
CORRESPONDENCE DATA	
Fax Number:	7325242808
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	732-524-2825
Email:	JNJUSPATENT@CORUS.JNJ.COM
Correspondent Name:	Philip S. Johnson, Esq.
Address Line 1:	One Johnson & Johnson Plaza
Address Line 4:	New Brunswick, NEW JERSEY 08933
ATTORNEY DOCKET NUMBER:	REDPOINT BIO CORPORATION
NAME OF SUBMITTER:	Geraldine Cooney
Signature:	/Geraldine Cooney/

CH \$160.00 7875452

Date:

06/24/2013

Total Attachments: 3

source=RedpointBio to Janssen#page1.tif

source=RedpointBio to Janssen#page2.tif

source=RedpointBio to Janssen#page3.tif

PATENT ASSIGNMENT

This **PATENT ASSIGNMENT** is made and entered into as of May 23, 2013, between **Redpoint Bio Corporation**, having a business address at 5501 Old York Road, Philadelphia, PA 19141, USA ("Assignor") and **Janssen Pharmaceuticals, Inc.**, a Pennsylvania corporation with an office at 1125 Trenton-Harbourton Road, Titusville, NJ 08560 ("Assignee").

RECITALS

WHEREAS, pursuant to, and upon the terms of, that certain Transfer Agreement and Bill of Sale, dated as of May 23, 2013, by and between Assignor and Assignee, Assignor has agreed to sell, convey, assign and transfer to Assignee, and Assignee has agreed to accept, Assignor's worldwide right, title and interest in, to and under certain patents and patent applications, utility models, and industrial designs, and all applications and registrations therefor, as set forth in Schedule A, which Schedule A is attached hereto and hereby made a part hereof, together with all non-provisionals, reissuances, continuations, divisions, renewals, revisions, extensions and reexaminations with respect thereto, and any other applications and patents sharing a claim of priority therewith (hereafter collectively referred to as "Patents").

WHEREAS, Assignor desires to transfer and assign to Assignee, and Assignee desires to accept the transfer and assignment of all of Assignor's right, title and interest in, to and under such Patents and in and to the inventions represented thereby.


NOW, THEREFORE, Assignor, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, does hereby sell, convey, transfer and assign to Assignee, and Assignee hereby accepts the sale, conveyance, transfer and assignment of Assignor's worldwide right, title and interest in, to and under the Patents, together with the right to claim priority in all countries in accordance with international law, any and all rights corresponding to said Patents in countries throughout the world, and all of Assignor's rights to sue for past, present or future infringement of said Patents worldwide together with all claims for damages by reason of past, present or future infringement of said Patents, and the right to sue for and collect the same for Assignee's own use and enjoyment, all to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had this Patent Assignment not been made.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, each of Assignor and Assignee has caused its respective duly authorized officer to execute this Patent Assignment as of the date first above written.


ASSIGNOR:

Redpoint Bio Corporation

By: 
Name: Scott Hurvitz
Title: President and CEO

ASSIGNEE:

Janssen Pharmaceuticals, Inc.

By: 
Name: STEVE BARIAHTARIS
Title: TREASURER

[Signature Page to the Patent Assignment]

Schedule A – Patents and Patent Applications

US 8193168

Country	Application number	Filing Date	Publication Number	Publication Date	Patent Number	Grant Date	Title	Priority Application
United States of America	US12/025,488	4-Feb-2008	US2008306030 (A1)	11-Dec-2008	US 8,193,168 (B2)	5-Jun-2012	Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release	61/016,394 filed 12-21-2007; which claims priority to 60/887,996 filed 02-02-2007

US 7674831

Country	Application number	Filing Date	Publication Number	Publication Date	Patent Number	Grant Date	Title	Priority Application
United States of America	11/843,411	22-Aug-2007	US2008249189 (A1)	9-Oct-2008	US 7,674,831 (B2)	9-Mar-2010	HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS	60/839,118 filed 08-22-2006

US 7749730

Country	Application number	Filing Date	Publication Number	Publication Date	Patent Number	Grant Date	Title	Priority Application
United States of America	11/592,180	3-Nov-2006	US2007111264 (A1)	17-May-2007	US 7,749,730 (B2)	6-Jul-2010	High throughput screening assay for the TRPM5 ion channel	60/732,636 filed 11-03-2005

US 7875452

Country	Application number	Filing Date	Publication Number	Publication Date	Patent Number	Grant Date	Title	Priority Application
United States of America	12/285,140	30-Sep-2008	US2009136975 (A1)	28-May-2009	US 7,875,452 (B2)	25-Jan-2011	Non-desensitizing mutant of the transient receptor potential TRPM5 ion channel	60/976,562 filed 10-01-2007